NEST trial - Whole body cooling for neonates undergoing extracorporeal membrane oxygenation (ECMO)
Extra corporeal membrane oxygenation (ECMO) is an invasive form of life support that can be used in patients with severe cardiorespiratory failure. Relatively mature (≥ 35 weeks gestational age) newborn infants have been the biggest patient group to receive ECMO and good evidence exists to support this practice. However data from randomised trials indicates that despite improved survival and reduced morbidity amongst newborns who receive ECMO, rates of neurodevelopmental impairment remain high. Accumulating evidence in other intensive care settings suggests that mild hypothermia at the time of going on to ECMO has the potential to reduce cerebral damage by providing a degree of neuroprotection. This trial assessed whether mild total body hypothermia can result in improved neurodevelopmental outcome after ECMO in the early neonatal period.
- Field D, Firmin R, Azzopardi D, Cowan F, Juszczak E, Brocklehurst P, the NEST Study Group. Neonatal ECMO Study of Temperature (NEST) - a randomised controlled trial. BMC Pediatr. 2010;10(1):24.
- Field D, Juszczak E, Linsell L, Azzopardi D, Cowan F, Marlow N, Edwards D, Group NSC. Neonatal ECMO study of temperature (NEST): a randomized controlled trial. Pediatrics. 2013;132(5):e1247-56.
- NPEU Contact:
- Ed Juszczak (firstname.lastname@example.org)
- Chief Investigators:
- David Field (external investigator)
- Related page:
- Last updated:
- Friday, 07 February 2014 20:17